Torrent Pharmaceuticals touched an intraday high of Rs 5,068.50 on the NSE on 5 August, driven by a 3.3% rise in Q1 profit to Rs 566 crore.

The company had actually reported its first-quarter results back on 30 July, though the numbers got wider attention this week after news agencies republished the syndicated filing on Tuesday, 4 August.

That’s likely what put the stock back in focus on Wednesday. For the quarter ended 30 June 2026, Torrent Pharmaceuticals posted a consolidated net profit of Rs 566 crore, up from Rs 548 crore in the same period last year, the company said in its regulatory filing.

Revenue from operations jumped to Rs 4,921 crore, well above the Rs 3,178 crore reported a year earlier. Expenses rose too, climbing to Rs 4,155 crore from Rs 2,403 crore.

The growth wasn’t confined to one market. India, the company’s largest, brought in Rs 2,157 crore, up 19% year-on-year. The US business grew faster still, up 36% to Rs 418 crore.

Brazil added 27% to reach Rs 277 crore, while Germany posted a smaller 3% gain to Rs 318 crore. It’s a fairly broad-based quarter, not one region carrying the whole story.

The stock’s reaction has been mixed, though. Even after touching that Rs 5,068.50 high earlier in Wednesday’s session.

At 10:17 am, shares slipped back and were last trading at Rs 4,974.00 on the NSE, down 1.11%, or Rs 56, from Tuesday’s close of Rs 5,030.

Over the past year, the stock has moved between Rs 3,480.60 and Rs 5,250, so Wednesday’s dip sits comfortably within that range rather than pointing to anything unusual.

Feeling overwhelmed by the markets? Let Tradz by EquityPandit be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!